证券代码：688114 证券简称：华大智造 公告编号：2025-039 深圳华大智造科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 24 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华路 9 号华大时空 中心 C 区国际会议中心 419 会议室 （五） 公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事3人，出席3人； 3、公司董事牟峰先生以代行董事会秘书身份出席了本次会议； （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 117 | | --- | --- | | 普通股股东人数 | 117 | | 2、出席会议的股东所持有的表决权数量 | 227,832,004 | | 普通股股东所持有表决权数量 | 227, ...

北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 E SR 在Uit E S Fr A YUAN LAW OFFICES 北京 BEIJING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 致:深圳华大智造科技股份有限公司 北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 嘉源(2025)-04-453 北京市嘉源律师事务所(以下简称"本所")接受深圳华大智造科技股份有 限公司〈以下简称"公司"〉的委托,根据《中华人民共和国公司法》（以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《深圳华大智造科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司2025年第二次临时股东大会(以下简称"本次股 东大会"）进行见证,并依法出具本法律意见书。 为 ...

Summary of Conference Call Records Industry Overview - The long-term care insurance (LTCI) market is expected to reach a scale of 2 trillion RMB, creating significant investment opportunities and driving the development of related companies. Currently, there are 180 million insured individuals, with only 1.3 million receiving benefits, indicating substantial room for penetration growth [1][5][8]. Key Points on Long-Term Care Insurance - The LTCI fund size is projected to grow from over 20 billion RMB to between 170 billion and 2 trillion RMB, representing a potential tenfold to hundredfold growth in this niche market. This growth is supported by overseas experiences showing excellent ROE and ROIC performance from related companies [2][9]. - By 2025, the number of disabled elderly individuals in China is expected to reach approximately 34 million, with annual care expenditures around 740 billion RMB. By 2050, this number may double to 64 million, with total expenditures reaching 1.7 trillion RMB [8][10]. Pharmaceutical and Medical Device Sector Insights - The innovative drug sector has experienced a rapid increase in stock prices, leading to a market correction. This adjustment is seen as normal, with expectations of a rebound in the near future. Key companies to watch include Innovent Biologics and CSPC Pharmaceutical Group [3][4]. - The innovative medical device sector is highlighted, with recommendations for companies such as BGI Genomics, Huatai Medical, and SINO Medical. SINO Medical's self-expanding stent is expected to receive approval by the end of August, while BGI Genomics benefits from AI medical applications [4][6]. Regulatory Support and Market Impact - The National Medical Products Administration (NMPA) has introduced policies to support high-end medical device innovation, particularly in robotics, advanced imaging equipment, AI-related devices, and new biomaterials. These policies are expected to enhance the approval efficiency and market performance of domestic innovative device companies [6][7]. - The surgical robotics sector is also noted for its potential, although it faces challenges from related healthcare policies. If favorable policies are introduced, the innovative device industry could see significant growth [7]. Investment Recommendations - The recommended investment portfolio includes East Sunshine Longjiang Pharmaceutical and Zhenbao Island, with East Sunshine's market capitalization projected to reach 45-50 billion HKD following successful hearings and upcoming data catalysts [6]. Zhenbao Island is expected to release positive information from its recent bidding success and breakthrough therapy plans [6]. Conclusion - The long-term care insurance market presents a significant growth opportunity, while the pharmaceutical and medical device sectors are poised for recovery and innovation, supported by favorable regulatory changes. Investors are encouraged to focus on leading companies in these areas for potential returns.

Core Viewpoint - The article highlights the resilience and innovative vitality of China's scientific instrument industry in the face of global challenges, showcasing significant growth in overseas revenue among domestic listed companies [2][6]. Group 1: Overview of Overseas Revenue - In 2024, the total overseas revenue of 43 domestic listed instrument companies reached 34.707 billion yuan, marking a new high [6][10]. - Over 60% of the companies reported revenue growth, with 21 companies achieving over 100 million yuan in overseas revenue [6][10]. - The top five companies by overseas revenue are Mindray Medical (16.434 billion yuan), Sunny Optical (9.602 billion yuan), Libang Instruments (1.098 billion yuan), BGI Genomics (913 million yuan), and Huashengchang (717 million yuan) [3][6]. Group 2: Performance Analysis - Among the 43 companies, 27 experienced stable or significant growth, with notable examples including Wanyi Technology, which saw a 447.23% increase in overseas revenue [7][12]. - Conversely, 14 companies faced revenue declines, such as Gaode Infrared, which reported a 50.76% drop [7][15]. - Mindray Medical's overseas revenue accounted for 44.75% of its total revenue, reflecting the effectiveness of its globalization strategy [10][17]. Group 3: Market Dynamics - The article indicates a shift in the market, with three companies achieving over 1 billion yuan in overseas revenue, while 18 companies fall within the 100 million to 1 billion yuan range [13]. - Companies with overseas revenue constituting over 10% of total revenue increased to 22, indicating a growing trend in international market engagement [17]. - Wanyi Technology's strategy of "product leadership, quality excellence, competitive pricing, and superior service" has led to substantial growth in overseas markets [13][17]. Group 4: Emerging Companies - New entrants like Titan Technology and Lihua Technology reported 100% growth in overseas revenue, reflecting successful market expansion strategies [14]. - Titan Technology leveraged partnerships with overseas distributors and acquisitions to enhance its competitive brand presence [14]. Group 5: Future Outlook - Despite external uncertainties, the overall trend indicates a robust commitment from Chinese companies to expand in international markets, suggesting a "fast forward" approach to globalization [17].

证券代码：688114 证券简称：华大智造 公告编号：2025-038 深圳华大智造科技股份有限公司 | 注册人名称 | | 昆山华大智造云影医疗科技有限公司 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 注册证编号 | | 苏械注准 20252061068 | | | | | | | 产品名称 | | 掌上无线彩色多普勒超声诊断仪 | | | | | | | 型号、规格 | | | | EF6-CLA、EF6-CLD、EF6-CLG、EF6-CLP、EF6-CLS | | | | | 适用范围 | 本产品适用于人体浅表器官及外周血管、腹部及外周血管的临床超声检 | | | | | | | | | | 查诊断。 | | | | | | | 发证机关 | | 江苏省药品监督管理局 | | | | | | | 有效期 2025 | | 年 6 月 17 日至 | 2030 | 年 | 6 月 | 16 | 日 | 二、对公司的影响 上述医疗器械注册证书的取得，有利于公司及子公司掌上超声业务工作的 全面开展，将进一步提高公司及子公司的 ...

深圳华大智造科技股份有限公司 2025 年第二次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 6 月 1 深圳华大智造科技股份有限公司 2025 年第二次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第二次临时股东大会会议须知 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造科技股份有限公司股东大会议事规则》及中国证券监督管理委员会、上海 证券交易所的有关规定，特制定本须知。 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请出 席大会的股东或其代理人或其他出席者务必准时到达会场签到确认参会资格，在 会议主持人宣布现场出席会议的股东和代理人人数及所 ...

深圳华大智造科技股份有限公司 2025 年第二次临时股东大会会议资料 深圳华大智造科技股份有限公司 会议资料 深圳华大智造科技股份有限公 会议资料 深圳华大智造科技股份有限公司 2025 年第二次临时股东大会会议资料 深圳华大智造科技股份有限公司 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造科技股份有限公司股东大会议事规则》及中国证券监督管理委员会、上海 证券交易所的有关规定，特制定本须知。 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请出 席大会的股东或其代理人或其他出席者务必准时到达会场签到确认参会资格，在 会议主持人宣布现场出席会议的股东和代理人人数及所持有的表决权数量之前， 会议登记应当终止，在此之后进场的股东 ...

Investment Logic - The company is deeply engaged in the gene sequencing field, with three main segments driving revenue growth. It is a rare domestic gene sequencer enterprise that has achieved core technology autonomy, with a product matrix covering full throughput and multiple scenarios, matching the technical level of international giants. The company is also expanding into laboratory automation and new businesses (BIT, ultrasound imaging, etc.), creating a comprehensive life science core tool product matrix that drives revenue growth from multiple angles. From 2017 to 2022, the company's revenue achieved an average annual compound growth of nearly 40%, and after the emergency demand disturbances gradually clear, revenue is expected to reach 3.013 billion yuan in 2024 (yoy +3.48%), with a narrowing of net profit losses, demonstrating resilience in performance [1]. Global Market Opportunities - The global gene sequencing market share is steadily increasing, and changes in the unreliable entity list are expected to bring significant opportunities, further expanding the company's growth space. The company, leveraging its product and brand strength, continues to accelerate global installations, with a market share exceeding 50% in newly tendered domestic markets in 2024, ranking first, and a global market share of 7.1%, with over 1,260 new installations. In March 2025, the Ministry of Commerce listed Illumina on the unreliable entity list, restricting its sales of sequencing equipment in the Chinese market, which presents a historic opportunity for domestic gene sequencer enterprises. The company, with its autonomous technology and supply chain system, as well as a full throughput and diversified product matrix, is expected to become a preferred alternative for research institutions, medical institutions, and third-party gene testing service providers. It is estimated that by 2025, the market space for instruments and reagent consumables will be 1.5 billion yuan and 2.3 billion yuan, respectively, and will reach 1.8 billion yuan and 5.4 billion yuan by 2030, which is 4-5 times the current business scale. In overseas markets, as patent litigation concludes, the company is rapidly increasing its installation and revenue scale in overseas regions and advancing localization in Asia-Pacific, Europe, and Africa, facilitating overseas market expansion [2]. AI Integration and Business Expansion - The company is building an "AI + BT + IT" intelligent sequencing ecosystem to enhance product value and company performance. It actively embraces AI technology transformation, integrating AI models such as DeepSeek-R1 and Evo 2 into αCube, providing comprehensive support for multi-omics and high-throughput sequencing needs. Additionally, AI technology is empowering instrument performance upgrades, launching laboratory intelligent automation (GLI) business and αLab, catering to demands in gene sequencing, synthetic biology, and other fields, thus aiding terminal applications and business expansion, opening up new growth trajectories [3]. Investment Recommendations - The company is a leading domestic gene sequencer with core technology autonomy, presenting a rare investment opportunity. The rapid development of gene sequencing business, coupled with Illumina's export restrictions to China, creates a historic opportunity for the company. The domestic market space is expected to expand again, while overseas market share is steadily increasing. Additionally, the laboratory automation business and new ventures are rapidly climbing, likely driving revenue and profit growth. Furthermore, in comparison to international giants like Tempus AI, the company's AI sequencing business ecosystem is expected to synergize with BGI's layout advantages, enhancing product added value and potentially leading to valuation premiums. Revenue projections for 2025-2027 are 3.585 billion yuan, 4.184 billion yuan, and 4.936 billion yuan, with year-on-year growth rates of 19.01%, 16.69%, and 17.98%, respectively. Net profit is projected to be 29 million yuan, 104 million yuan, and 219 million yuan, with year-on-year growth rates of 104.79%, 262.33%, and 110.26%, respectively, marking the first coverage with a "recommended" rating [4].

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]